Cabometyx 40 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DR26FMDT1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,644
Award facts
- Contract value 100% obligated
- $33,644.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $33,644.36 to DMS Pharmaceutical Group Inc. for the supply of Cabometyx 40 mg tablets (30-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order has an ultimate completion date of October 23, 2025, and will be performed at the vendor's Park Ridge location. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
The PPV-G GEN V program positions DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's indefinite delivery contract, designated SPE2DR and valued at $499.99 million, features a 30-month base period with three 30-month option periods extending through December 31, 2036. The company's established performance on numerous delivery orders across diverse therapeutic categories, including oncology treatments, immunosuppressants, vaccines, and specialty pharmaceuticals, demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FMDT1?
SPE2DR26FMDT1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DR26FMDT1 worth?
The government has obligated $33,644 on SPE2DR26FMDT1.
Is contract SPE2DR26FMDT1 an order under another contract?
Yes. SPE2DR26FMDT1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDT1 competed?
The extent of competition for SPE2DR26FMDT1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award